1. Biopharmaceutics Research Group, Airways Disease, National Heart and Lung Institute, Imperial College, London, UK, AstraZeneca R&D, Respiratory and Inflammation Research Area, Alderley Park, Macclesfield, Cheshire, UK, Department of Experimental Medical Science, Division of Vascular and Airway Research, Lund University, Lund, Sweden, Medical Research Council Laboratory of Molecular Biology, Cambridge, UK, and Integrated DNA Technologies, BVBA, Leuven, Belgium